Merus Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Merus stock.
View analyst ratings for Merus or view top-rated stocks.

7 analysts have issued 1 year target prices for Merus' shares. Their MRUS stock forecasts range from $33.00 to $45.00. On average, they predict Merus' stock price to reach $41.43 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price.
View analysts' price targets for Merus or view top-rated stocks among Wall Street analysts.

Merus' stock was trading at $31.80 at the beginning of 2022. Since then, MRUS shares have decreased by 30.6% and is now trading at $22.08.
View the best growth stocks for 2022 here.

Merus is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Merus.

Merus (NASDAQ:MRUS) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.23. The biotechnology company had revenue of $11.66 million for the quarter, compared to analyst estimates of $8.55 million. Merus had a negative trailing twelve-month return on equity of 29.02% and a negative net margin of 143.77%.
View Merus' earnings history.

Some companies that are related to Merus include Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), CureVac (CVAC) and Indivior (INVVY).
View all of MRUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.79%), Frazier Life Sciences Management L.P. (1.44%), BlackRock Inc. (1.23%), Ghost Tree Capital LLC (0.92%), Lord Abbett & CO. LLC (0.91%) and Silverarc Capital Management LLC (0.75%). Company insiders that own Merus stock include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby, Peter B Silverman and Value Fund L P Biotechnology.
View institutional ownership trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Platinum Investment Management Ltd., Acadian Asset Management LLC, Kynam Capital Management LP, and Northern Trust Corp. Company insiders that have sold Merus company stock in the last two years include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby, and Peter B Silverman.
View insider buying and selling activity for Merus or view top insider-selling stocks.

MRUS stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Paradigm Biocapital Advisors LP, Lord Abbett & CO. LLC, Eversept Partners LP, Tekla Capital Management LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, and Woodline Partners LP.
View insider buying and selling activity for Merus or or view top insider-buying stocks.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRUS stock can currently be purchased for approximately $22.08.

Merus (NASDAQ:MRUS) has a market capitalization of $961.58 million and generates $49.11 million in revenue each year. The biotechnology company earns $-66.82 million in net income (profit) each year or ($1.87) on an earnings per share basis.

Merus employs 117 workers across the globe.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for Merus is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at [email protected].